Cargando…

The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait

Purpose: To evaluate metabolic control in patients with type 2 diabetes at Dasman Diabetes Institute (DDI, Kuwait), a specialist diabetes clinic and research center, and to investigate its association with patient demographics and clinical characteristics. Methods: Data from 963 patients with type 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Qaddoumi, Mohammad, Al-Khamis, Yousuf, Channanath, Arshad, Tuomilehto, Jaakko, Badawi, Dalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607397/
https://www.ncbi.nlm.nih.gov/pubmed/31297092
http://dx.doi.org/10.3389/fendo.2019.00412
_version_ 1783432088702156800
author Qaddoumi, Mohammad
Al-Khamis, Yousuf
Channanath, Arshad
Tuomilehto, Jaakko
Badawi, Dalia
author_facet Qaddoumi, Mohammad
Al-Khamis, Yousuf
Channanath, Arshad
Tuomilehto, Jaakko
Badawi, Dalia
author_sort Qaddoumi, Mohammad
collection PubMed
description Purpose: To evaluate metabolic control in patients with type 2 diabetes at Dasman Diabetes Institute (DDI, Kuwait), a specialist diabetes clinic and research center, and to investigate its association with patient demographics and clinical characteristics. Methods: Data from 963 patients with type 2 diabetes were retrospectively collected from the Knowledge Based Health Records maintained at DDI for patients who attended DDI during 2011–2014. The collected data included patient demographics, clinical characteristics, and anti-diabetic medications. Student's t-test was used to evaluate the differences in mean values between poor and good glycemic control groups. Categorical variables were assessed using chi-square analysis with Fisher's exact test for small data sets. Results: The patients' mean age was 53.0 ± 9.5 years with equal number of males and females. Females (34.4 ± 7.2 kg/m(2)) had a higher mean body mass index than males (32.1 ± 6.4 kg/m(2)). The mean fasting blood glucose and HbA1c levels were 9.6 ± 3.8 mmol/L and 8.5 ± 1.8%, respectively. Dyslipidemia (46%) and hypertension (40%) were the most common comorbidities, whereas nephropathy (36%) and neuropathy (35%) were the most common diabetic complications. The most commonly used anti-diabetic medication was metformin (55%). Factors significantly associated with poor glycemic control (HbA1c level ≥ 7%) included insulin use; neuropathy or foot ulcers as diabetic complications; and elevated systolic blood pressure and total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose levels. Factors significantly associated with good glycemic control included metformin use and elevated high-density lipoprotein cholesterol level. The proportion of patients with good glycemic control (HbA1c level < 7%) was 29.5%. A large proportion of the patients with poor glycemic control were only administered monotherapy drugs, and two-thirds of the patients were obese. Further, the American Diabetes Association (ADA) recommendations for blood pressure and LDL cholesterol level were met (62 and 63%, respectively) by follow-up year 4. Conclusion: The therapeutic management of type 2 diabetes in Kuwait is suboptimal. Therapeutic strategies should ensure better adherence to ADA guidelines, evaluate the high obesity rates, and adherence to lifestyle recommendations by patients, and continually promote diabetes education and self-empowerment.
format Online
Article
Text
id pubmed-6607397
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-66073972019-07-11 The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait Qaddoumi, Mohammad Al-Khamis, Yousuf Channanath, Arshad Tuomilehto, Jaakko Badawi, Dalia Front Endocrinol (Lausanne) Endocrinology Purpose: To evaluate metabolic control in patients with type 2 diabetes at Dasman Diabetes Institute (DDI, Kuwait), a specialist diabetes clinic and research center, and to investigate its association with patient demographics and clinical characteristics. Methods: Data from 963 patients with type 2 diabetes were retrospectively collected from the Knowledge Based Health Records maintained at DDI for patients who attended DDI during 2011–2014. The collected data included patient demographics, clinical characteristics, and anti-diabetic medications. Student's t-test was used to evaluate the differences in mean values between poor and good glycemic control groups. Categorical variables were assessed using chi-square analysis with Fisher's exact test for small data sets. Results: The patients' mean age was 53.0 ± 9.5 years with equal number of males and females. Females (34.4 ± 7.2 kg/m(2)) had a higher mean body mass index than males (32.1 ± 6.4 kg/m(2)). The mean fasting blood glucose and HbA1c levels were 9.6 ± 3.8 mmol/L and 8.5 ± 1.8%, respectively. Dyslipidemia (46%) and hypertension (40%) were the most common comorbidities, whereas nephropathy (36%) and neuropathy (35%) were the most common diabetic complications. The most commonly used anti-diabetic medication was metformin (55%). Factors significantly associated with poor glycemic control (HbA1c level ≥ 7%) included insulin use; neuropathy or foot ulcers as diabetic complications; and elevated systolic blood pressure and total cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides, and fasting blood glucose levels. Factors significantly associated with good glycemic control included metformin use and elevated high-density lipoprotein cholesterol level. The proportion of patients with good glycemic control (HbA1c level < 7%) was 29.5%. A large proportion of the patients with poor glycemic control were only administered monotherapy drugs, and two-thirds of the patients were obese. Further, the American Diabetes Association (ADA) recommendations for blood pressure and LDL cholesterol level were met (62 and 63%, respectively) by follow-up year 4. Conclusion: The therapeutic management of type 2 diabetes in Kuwait is suboptimal. Therapeutic strategies should ensure better adherence to ADA guidelines, evaluate the high obesity rates, and adherence to lifestyle recommendations by patients, and continually promote diabetes education and self-empowerment. Frontiers Media S.A. 2019-06-26 /pmc/articles/PMC6607397/ /pubmed/31297092 http://dx.doi.org/10.3389/fendo.2019.00412 Text en Copyright © 2019 Qaddoumi, Al-Khamis, Channanath, Tuomilehto and Badawi. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Qaddoumi, Mohammad
Al-Khamis, Yousuf
Channanath, Arshad
Tuomilehto, Jaakko
Badawi, Dalia
The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title_full The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title_fullStr The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title_full_unstemmed The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title_short The Status of Metabolic Control in Patients With Type 2 Diabetes Attending Dasman Diabetes Institute, Kuwait
title_sort status of metabolic control in patients with type 2 diabetes attending dasman diabetes institute, kuwait
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6607397/
https://www.ncbi.nlm.nih.gov/pubmed/31297092
http://dx.doi.org/10.3389/fendo.2019.00412
work_keys_str_mv AT qaddoumimohammad thestatusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT alkhamisyousuf thestatusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT channanatharshad thestatusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT tuomilehtojaakko thestatusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT badawidalia thestatusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT qaddoumimohammad statusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT alkhamisyousuf statusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT channanatharshad statusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT tuomilehtojaakko statusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait
AT badawidalia statusofmetaboliccontrolinpatientswithtype2diabetesattendingdasmandiabetesinstitutekuwait